Skip to Content
Merck
  • Colorectal cancer prevention in inflammatory bowel disease and the role of 5-aminosalicylic acid: a clinical review and update.

Colorectal cancer prevention in inflammatory bowel disease and the role of 5-aminosalicylic acid: a clinical review and update.

Inflammatory bowel diseases (2007-10-13)
David T Rubin, Marcia R Cruz-Correa, Christoph Gasche, Jeremy R Jass, Gary R Lichtenstein, Elizabeth A Montgomery, Robert H Riddell, Matthew D Rutter, Thomas A Ullman, Fernando S Velayos, Steven Itzkowitz
ABSTRACT

A roundtable consensus meeting was held to consolidate current knowledge on the etiology of colorectal cancer in patients with inflammatory bowel disease and to review current strategies, both diagnostic and preventive, specifically addressing the role of 5-aminosalicylic acid. Specific topics that were addressed included: the epidemiology of colorectal cancer, including an assessment of risk factors and the impact of colonoscopy on colorectal cancer incidence and mortality; the origin and evolution of dysplasia nomenclature and the natural history of dysplasia; review of the experience of St. Mark's Hospital (London) as gleaned from its surveillance database; mechanisms by which 5-aminosalicylic acid is thought to exert a chemopreventive effect; the potential future role of 5-aminosalicylic acid in chemopreventive strategies; chemoprevention in familial adenomatous polyposis; and other future research directions. This article provides a comprehensive overview of the issues discussed and should act as a guide to shaping the design of future studies in this area.

MATERIALS
Product Number
Brand
Product Description

Mesalazine for system suitability, European Pharmacopoeia (EP) Reference Standard
Supelco
Mesalamine, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
5-Aminosalicylic acid, ≥99%
Mesalazine, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
5-Aminosalicylic acid, 95%